Compare Krispy Kreme Inc (DNUT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs TG Therapeutics Inc — how do they compare? Krispy Kreme Inc trades at $3.31 (market cap $537.85M), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 14.2× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DNUT | TGTX | |
|---|---|---|
Market Cap | $537.85M | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $59.06 |
52-Week Low | $2.92 | $26.94 |
Enterprise Value | $1.78B | $7.84B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.31, up 5.41% today, amid a bearish technical trend. The company reported a Q2 2026 loss of $0.03 per share, beating estimates, but revenue declined 12.8% year-over-year due to refranchising. Net income margin remains negative at -6.16%, though the CEO highlights turnaround progress with margin improvement and deleveraging. Cash flow from operations was $33.92 million in 2025, supporting liquidity.
The stock presents a high-risk opportunity with a mixed outlook. Analysts are cautiously optimistic (50% buy ratings), but persistent losses and competitive pressures pose significant risks. Valuation metrics like P/S of 0.36 suggest potential undervaluation if the turnaround succeeds, yet execution challenges and debt levels require close monitoring.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
